FY2027 Action Alert!
The Senate has taken an important step forward for the Duchenne and Becker community. Now, we need the House of Representatives to follow suit.
The Senate Appropriations Committee has released its FY27 spending bills, reflecting several important priorities that PPMD and our advocates have worked hard to advance, including investments in Duchenne and Becker research, disease surveillance, next-generation therapies, and newborn screening.
Now, we need your help ensuring these priorities are reflected in the House of Representatives' FY27 appropriations legislation.
Take Action: Contact your Representative and urge them to support the following priorities in FY27 appropriations:
- CDC Research and Disease Surveillance: Support increased funding for muscular dystrophy research and surveillance initiatives at the CDC, including efforts to better understand Duchenne and Becker outcomes across the lifespan, improve adult care, and address critical areas such as bone health, cardiovascular and cognitive function.
- Department of Defense Research Funding: Maintain at least $12.5 million for the CDMRP to advance innovative, peer-reviewed research and accelerate progress toward treatments and cures.
- NIH Research and Next-Generation Therapies: Support increased NIH funding and a coordinated, multi-Institute strategy to accelerate DNA- and RNA-directed platform technologies, with particular attention to rare and challenging genotypes that may be underserved by current therapeutic development approaches.
- Newborn Screening Implementation: Support states as they work to implement Duchenne newborn screening following its addition to the Recommended Uniform Screening Panel (RUSP) in December 2025. Ensure that federal resources are available to help states successfully implement screening and connect newborns to timely diagnosis, care, and treatment.
Why This Matters
For individuals and families living with Duchenne and Becker, these investments are not simply line items in a federal budget. They represent opportunities for earlier diagnosis, better care, expanded treatment options, and continued scientific progress.
The Senate has recognized the importance of these priorities. Now, the House must do its part.
Your voice can help make a difference.
Contact your Representative today and urge them to champion these priorities in the FY27 appropriations process. Ask them to support funding and report language that advance research, improve care and surveillance, and ensure successful implementation of Duchenne newborn screening.
Target Search
Thank you for advocating for our community!



